Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial.
Joan T MerrillYoshiya TanakaDavid D'CruzKarina Vila-RiveraDaniel SiriXiaofeng ZengAmit SaxenaMartin AringerKristin M D'SilvaLing ChengMohamed-Eslam F MohamedLucia SiovitzSumit BhatnagarMarie-Claude GaudreauThao T DoanAlan FriedmanPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2024)
Upadacitinib 30 mg alone or in combination with elsubrutinib (ABBV-599 high dose) demonstrated significant improvements in SLE disease activity and reduced flares and were well tolerated through 48 weeks.